ArticleDer Urologe. Ausg. A2012
[Therapy selection in patients with advanced bladder cancer. Is molecular biology helpful?].
Article in Der Urologe. Ausg. A, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of patients with advanced bladder cancer is still limited by a high rate of systemic progression. In addition to extended lymph node dissection, perioperative chemotherapy has been shown to improve the outcome after cystectomy. The role of neoadjuvant and adjuvant therapies are still a matter of controversial debate: there is an overtreatment of patients on the one hand but other patients are undertreated and do not receive chemotherapy because the progression risk may be underestimated on the basis of clinical and histopathological parameters. Improved cure rates can be achieved by new biomarkers defining the individual risk of systemic progression and predicting the response probability of the individual patient.A number of recent publications demonstrated that molecular signatures of the primary tumor can define the metastatic risk or correlate with chemotherapy response. Furthermore, it is essential to understand resistance mechanisms and to develop new targeted therapies based on knowledge of bladder tumor biology. This paper gives an overview concerning the role of molecular biology for therapy decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.